Drug combination could set norms for advanced kidney cancer treatment
Category: #health  By Pankaj Singh  Date: 2019-02-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Drug combination could set norms for advanced kidney cancer treatment

Reporting the results from a phase 3 clinical trial, an investigator from Dana-Farber Cancer Institute revealed that the combination of two drugs could be a first-line, new standard treatment for patients that are suffering from metastatic kidney cancer.

Sources familiar with the matter cited that patients who received the targeted agent axitinib, along with avelumab, an immunotherapy drug, had a considerable advantage in progression-free survival in comparison to those that received a targeted drug sunitinib (Sutent). Sunitinib supposedly has been a standard treatment for the most common form of kidney cancer- advanced clear cell renal cell carcinoma.

Lank Center’s Director for Genitourinary Oncology at Dana-Farber and senior and co-corresponding author of the JAVELIN Renal 101 trial report in the New England Journal of Medicine (NEJM), Toni K. Choueiri, MD, mentioned that the patients who received the drug combination had a higher response rate, which means their tumors shrank, in comparison to those who received only sunitinib.

Sources added that although the progression-free survival was enhanced with the combination treatment, added follow-ups are required for showing if the two-drug therapy expands to overall survival in comparison with the standard regimen.

Choueiri said that the drug combination is certainly better than sunitinib, which would hopefully lead to the U.S. FDA approval soon. The analysis apparently revealed that all the subgroups – poor-risk, intermediate, and good patient – benefitted from the combination treatment.

Choueiri has recently given an oral presentation on the same topic at the 2019 Genitourinary Cancers Symposium in San Francisco. Those results were concurrently published in the New England Journal of Medicine.

Choueiri further said that the combination is an important option for patients with advanced disease. The contributions made in the advanced kidney cancers is further pushing the envelope and the treatments might not be curative; however, patients are living longer, and the disease is becoming more chronic.



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...